Mar 21, 2018 ... Virgil v. Janssen Research & Development LLC et al (2:18-cv-03036), Louisiana Eastern District Court, Filed: 03/21/2018 - PacerMonitor Mobile Federal and Bankruptcy Court PACER Dockets.
Apr 11, 2018 ... Other case filed on April 11, 2018 in the Missouri Eastern District Court.
Jan 8, 2018 ... JANSSEN PHARMACEUTICALS INC JOHNSON JOHNSON JANSSEN RESEARCH DEVELOPMENT LLC EXCERPTA MEDICA INCORPORATED AND ELSEVIER INC. ... All of the cases in this mass tort involve male plaintiffs who allege they developed gynecomastia as a result of ingesting Risperdal.
Oct 19, 2015 ... Liu v. Janssen Research & Development, LLC – $8 Million. JURY HITS PHARMACEUTICAL GIANT WITH $8 MILLION VERDICT FOR DEADLY DRUG TRIAL ... “Leo was tragically used as a human guinea pig to test a dangerous drug without taking proper safety precautions, all in the name of profits, ” said ...
Jan 30, 2015 ... PLEDGER, et al. -vs- JANSSEN, et al. -. 6. 1. 2006, I think she had a real good guide there. 2 on Page 10 out of 19, which we just printed. 3 out. And in that case, I agree with her, she. 4 thought it was -- extensive cross-examination. 5 she permitted as follows: The total number. 6 of cases he has testified; the ...
Dec 16, 2015 ... Full-length transcript assembly is a challenge with current short read sequence technologies (Bradnam et al., 2013; Steijger et al., 2013). ..... H.M., H.K., M.F., and W.C.D. are employees of Janssen Research & Development, LLC, and of Johnson and Johnson, Inc., and stockholders of Johnson and Johnson, ...
Primarily, all the SGLT2 inhibitors act by an insulin-independent mechanism, thereby providing a complementary effect when used in combination with other oral ..... Dr. William Canovatchel is an employee of Janssen Research and Development, LLC. ..... Schroeder M, Taieb V, Pacou M, Ho S, Nielsen AT, Schubert A, et al.
Oct 15, 2015 ... Raritan, NJ; 9Janssen Research & Development, LLC, Spring House, PA; 10Janssen Research & Development, Division of Janssen Pharmaceutica NV, ..... planned, requiring screening of ;364 patients based on the assumption that the non-GCB subtype constitutes ;45% of all DLBCL. 1894. OFFNER et al.
Jul 31, 2015 ... This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B- cell-like diffuse large B-cell lymphoma (non-GCB DLBCL), centrally ...